Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis
Por:
Medina-Fernandez F.J., Escribano B.M., Luque E., Caballero-Villarraso J., Gomez-Chaparro J.L., Feijoo M., Garcia-Maceira F.I., Pacual-Leone A., Drucker-Colin R., Tunez I.
Publicada:
1 mar 2018
Categoría:
Neuroscience (miscellaneous)
Resumen:
The effects of transcranial magnetic stimulation (TMS), natalizumab (nata), dimethyl fumarate (DMF) and dexamethasone (DEX) on clinical score and oxidative stress produced by a single dose of myelin oligodendrocyte glycoprotein (MOG) in tail of Dark Agouti rats was studied. TMS (60 Hz and 0.7 mT), nata (5 mg/kg), DMF (15 mg/kg) and DEX (300 µg/kg) was applied for 21 after the administration of MOG (150 µg). We estimated clinical score, as well as lipid peroxides, carbonylated proteins and reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio content in brain, spinal cord and blood. MOG triggered significant increase in clinical score and in the levels of lipid peroxides and carbonylated proteins levels, but reduced GSH/GSSG ratio in brain, spinal cord and blood. Both TMS and clinical treatments, although TMS more significantly, decreased the changes caused by MOG administration. These results support the antioxidant and neuroprotective action of TMS, as well as an activity higher than other clinical treatments. © 2017 Elsevier Inc.
Filiaciones:
Medina-Fernandez F.J.:
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain
Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba, Spain
Escribano B.M.:
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain
Departamento de Biologia Celular, Fisiología e Inmunología, Universidad de Cordoba, Cordoba, Spain
Luque E.:
Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba, Spain
Departmento de Ciencias Morfologicas, Seccion de Histologia, Facultad de Medicina y Enfermeria, Universidad de Cordoba, Spain
Caballero-Villarraso J.:
Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba, Spain
Unidad de Gestion Clinica de Analisis Clinicos, Hospital Universitario Reina Sofia de Cordoba, Cordoba, Spain
Gomez-Chaparro J.L.:
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain
Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba, Spain
Feijoo M.:
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain
Garcia-Maceira F.I.:
Canvax Biotech S.L., Cordoba, Spain
Pacual-Leone A.:
Berenson-Allen Center for Noninvasive Brain Stimulation, Division of Cognitive Neurology, Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States
Drucker-Colin R.:
Departmento de Neuropatología Molecular, Instituto de Fisiologia Celular, Universidad Nacional Autonoma de Mexico (UNAM), Ciudad de Mexico, D.F., Mexico
Tunez I.:
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba, Córdoba, Spain
Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba, Spain
|